While I select my investments based on return on investment, I select my charities based on impact. Year after year, Damon Runyon selects the best new minds in cancer research and funds their bold ideas for preventing and curing cancer. Year after year, its scientists go on to make major breakthroughs. That’s real impact.”
The Damon Runyon Board is extraordinarily committed to supporting the best young minds in cancer research. We are singularly focused on this mission.”
Chairman
Alan M. Leventhal
Chairman and CEO Beacon Capital Partners, LLC Boston, Massachusetts
Vice Chair, Scientific Programs
William G. Kaelin, Jr., MD
Professor, Department of Medicine
Dana-Farber Cancer Institutue
Boston, Massachusetts
Vice Chair, Investments and Treasurer
Leon G. Cooperman
Chairman and CEO Omega Advisors, Inc.
New York, New York
Vice Chair, Audit Committee and Secretary
Sanford W. Morhouse, Esq.
Of Counsel
Schulte Roth and Zabel LLP
New York, New York
Vice Chair, Board Development
Michael L. Gordon
Chief Executive Officer and Chief Investment Officer
Angelo, Gordon & Company LP
New York, New York
Vice Chair, Development and Communications
David M. Beirne
General Partner, 10X Capital
Coral Gables, Florida
Steven J. Burakoff, MD
Dean for Cancer Innovation
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, New York
Deborah J. Coleman
Legal Counsel
Convexity Capital Management LP
Boston, Massachusetts
Robyn Coles
President
TRATE Properties
Boston, Massachusetts
Gary E. Erlbaum
President
Greentree Properties
Ardmore, Pennsylvania
Thomas J. Fahey, Jr., MD
Senior Vice President Emeritus
Memorial Sloan-Kettering Cancer Center
New York, New York
Buck French
General Partner
10X Capital
San Francisco, California
Elaine V. Fuchs, PhD
Rebecca C. Lancefield Professor
Investigator, Howard Hughes Medical Institute
Head, Laboratory of Mammalian Cell Biology and Development
The Rockefeller University
New York, New York
Receiving a Damon Runyon Fellowship had a tremendous impact on my scientific career. I also have been fortunate to mentor new Damon Runyon scientists in my lab who have gone on to have exemplary independent careers. Damon Runyon builds generations of scientific leaders and mentors.”
Elaine Fuchs, PhD
(Damon Runyon Fellow ‘77-‘79)
Richard B. Gaynor, MD
President of Research and Development
Neon Therapeutics
Cambridge, Massachusetts
Todd R. Golub, MD
Chief Scientific Officer Director, Cancer Program
The Broad Institute of MIT and Harvard
Charles A. Dana Investigator in Human Cancer Genetics at the Dana-Farber Cancer Institute
Professor of Pediatrics at Harvard Medical School
Investigator, Howard Hughes Medical Institute
Cambridge, Massachusetts
Scott Greenstein
President, Chief Content Officer
SiriusXM
New York, New York
Steve Hayden
Vice Chairman & Chief Creative Officer (Retired)
Ogilvy & Mather Worldwide
New York, New York
Jay W. Ireland
President and CEO
GE Africa
Nairobi, Kenya
Morana Jovan-Embiricos, PhD
Managing Partner
F2 Capital Ventures, LLP
London, UK
Steven A. Kandarian
Chairman, President and CEO
MetLife, Inc
New York, New York
Noah Knauf
Managing Director
Warburg Pincus
San Francisco, California
Gabrielle Layton, PhD
Palo Alto, California
David M. Livingston, MD
Deputy Director
Dana-Farber/Harvard Cancer Center
Emil Frei Professor of Genetics and Medicine
Harvard Medical School Boston, Massachusetts
David G. Marshall
Chairman and CEO
Amerimar Realty Company
Philadelphia, Pennsylvania
John H. Myers
Director
Academy Securities
Fairfield, Connecticut
Richard J. O’Reilly, MD
Chief, Pediatric Bone Marrow Transplant Service
Claire L. Tow Chair in Pediatric Oncology Research
Memorial Sloan Kettering Cancer Center
New York, New York
Andrew S. Rachleff
President & CEO
Wealthfront, Inc.
Palo Alto, California
William Raveis, Jr.
Founder, Chairman and CEO
William Raveis Real Estate, Mortgage & Insurance
Southport, Connecticut
In Silicon Valley, we have witnessed brilliant young minds with bold ideas change the world. Damon Runyon makes this happen for cancer research. It identifies top emerging talent and encourages their high risk/high reward ideas. The payoff has been generations of game-changers.”
Andy and Debbie Rachleff
Michael V. Seiden, MD, PhD
Senior Vice President and Chief Medical Officer
McKesson Specialty Health
The US Oncology Network
The Woodlands, Texas
Karen D. Seitz
Founder and Managing Director
Fusion Partners
New York, New York
Nancy Simonian, MD
Chief Executive Officer
Syros Pharmaceuticals
Watertown, Massachusetts
Cynthia Sulzberger
Palm Beach, Florida
Peter Van Camp
Executive Chairman
Equinix, Inc.
Redwood City, California
James A. Wells, PhD
Chairman, Dept. of Pharmaceutical Chemistry
University of California at San Francisco
San Francisco, California
